Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Verapamil
Drug ID BADD_D02348
Description Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina,[L8791] and was the first calcium channel antagonist to be introduced into therapy in the early 1960s.[A188514] It is a member of the non-dihydropyridine class of calcium channel blockers, which includes drugs like [diltiazem] and [flunarizine], but is chemically unrelated to other cardioactive medications.[L8791] Verapamil is administered as a racemic mixture containing equal amounts of the S- and R-enantiomer, each of which is pharmacologically distinct - the S-enantiomer carries approximately 20-fold greater potency than the R-enantiomer, but is metabolized at a higher rate.[A188435]
Indications and Usage Verapamil is indicated in the treatment of vasopastic (i.e. Prinzmetal's) angina, unstable angina, and chronic stable angina. It is also indicated to treat hypertension, for the prophylaxis of repetitive paroxysmal supraventricular tachycardia, and in combination with digoxin to control ventricular rate in patients with atrial fibrillation or atrial flutter.[L8791] Given intravenously, it is indicated for the treatment of various supraventricular tachyarrhythmias, including rapid conversion to sinus rhythm in patients with supraventricular tachycardia and for temporary control of ventricular rate in patients with atrial fibrillation or atrial flutter.[L10481] Verapamil is commonly used off-label for prophylaxis of cluster headaches.[A13983]
Marketing Status approved
ATC Code C08DA01
DrugBank ID DB00661
KEGG ID D02356
MeSH ID D014700
PubChem ID 2520
TTD Drug ID D0R0FE
NDC Product Code 70966-0029
UNII CJ0O37KU29
Synonyms Verapamil | Iproveratril | Cordilox | Dexverapamil | Verapamil Hydrochloride | Hydrochloride, Verapamil | Finoptin | Izoptin | Isoptine | Isoptin | Lekoptin | Calan | Falicard
Chemical Information
Molecular Formula C27H38N2O4
CAS Registry Number 52-53-9
SMILES CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Prostate cancer21.04.02.002; 16.25.01.0010.000099%Not Available
Therapeutic reaction time decreased08.06.01.015--Not Available
Erectile dysfunction21.03.01.007; 19.08.04.001--
Inner ear disorder04.04.02.002--Not Available
Drug intolerance08.06.01.0130.000148%Not Available
Psychotic disorder19.03.01.002--
Renal impairment20.01.03.010--Not Available
Mixed liver injury09.01.07.0150.000099%Not Available
Treatment failure08.06.01.0170.000099%Not Available
Brain injury19.07.03.007; 17.11.01.0030.000148%Not Available
Acute kidney injury20.01.03.0160.000643%
Atrioventricular dissociation02.03.01.0120.000099%Not Available
Atrial thrombosis02.11.01.002; 24.01.05.0050.000148%Not Available
Tricuspid valve disease02.07.05.0040.000099%
Acute lung injury22.01.03.0100.000099%Not Available
Distributive shock24.06.02.0220.000099%Not Available
Myocardial stunning02.02.02.021; 24.04.04.0240.000198%Not Available
Anaesthesia oral17.02.06.037; 07.05.05.0260.000099%Not Available
Blood brain barrier defect24.03.05.014; 17.08.02.0280.000099%Not Available
Cardiac septal hypertrophy02.04.02.0390.000099%Not Available
Drug ineffective for unapproved indication12.09.02.002; 08.06.01.0380.000099%Not Available
Therapeutic product effect decreased08.06.01.050--Not Available
The 8th Page    First    Pre   8    Total 8 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene